~~<i id='0FAF74C1E2'><strike id='0FAF74C1E2'><tt id='0FAF74C1E2'><pre id='0FAF74C1E2'></pre></tt></strike></i>~~

Home» Wikipedia» knowledge

knowledge

author：comprehensive 2025-10-06 08:58:05 Page View：6

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Science's Marcia McNutt, trailblazer for women, encounters sexism scandal
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

focus

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Novo: Oral version of Ozempic leads to 15% weight loss

LISELOTTESABROE/AFP/GettyImagesAnoralversionofsemaglutide,thedrugmarketedasOzempicandWegovy,ledtodra

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Sea level rise could wash away turtle breeding grounds around the world, researchers say

1:14AseaturtleisseenatSeaTurtlesResearchRescueandRehabilitationCenterinMugla,TurkeyonAug.18,2021.Seb

WSS

knowledge

knowledge

explore

focus

Sea level rise could wash away turtle breeding grounds around the world, researchers say